medigraphic.com
Revista Médica Sinergia

2021, Number 02

Next >>

Revista Médica Sinergia 2021; 6 (02)

Initial clinical management of amioatrophic lateral sclerosis

Charpentier MRJ, Loaiza QKV

Language: Spanish
References: 18
Page: 1-12
PDF size: 187.26 Kb.


ABSTRACT

Amyotrophic lateral sclerosis is a progressive disease characterized by degeneration of motor neurons in the brain and spinal cord. There are two fundamental forms of this disease: the sporadic form and the familial form. There is still no clarity about its etiology. Clinical manifestations include signs of damage to the upper and lower motor neurons, both in the extremities and in the bulbar musculature. The diagnosis continues to be fundamentally clinical, supported by neurophysiological studies. There is no curative treatment. Riluzole is the first-line drug treatment that has been shown to delay the normal course of the disease. Edaravone is approved by the FDA for use in this disease in conjunction with riluzole.


REFERENCES

  1. Brown R, Al-Chalabi A. Amyotrophic Lateral Sclerosis. NEJM. 2017;(N Engl J Med 2017; 377):162-172. https://doi.org/10.1056/NEJMra1603471

  2. Jameson J, Kasper D, Fauci A, Hauser S, Longo D, Loscalzo J et al. Harrison's principles of internal medicine, 20e. 20th ed. Mc Graw Hill Education; 2018; 7639-7656.

  3. Perez S, et al. Abordaje de la esclerosis lateral amiotrófica [Internet]. [Consultado 24 Abril 2020]. Madrid, España: Ministerio de sanidad, servicios sociales e igualdad. 2018. Disponible en: https://adelaweb.org/wpcontent/ uploads/2017/11/Asociacion-adEla_Plan-Nacional-de-ELA.pdf

  4. Filippini T, Fiore M, Tesauro M , Malagoli C. Clinical and Lifestyle Factors and Risk of Amyotrophic Lateral Sclerosis [Internet]. [Consultado 25 Abril 2020]. Res. Public Health 2020, 2020. Disponible en:https://res.mdpi.com/d_attachment/ijerph/ijerph-17-00857/article_deploy/ijerph-17-00857-v2.pdf

  5. Ryan M, Heverin M, McLaughlin R, et al. Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis. JAMANeurology. 2020;76(11):1367-1374. https://doi.org/10.1001/jamaneurol.2019.2044

  6. Massachusetts Medical Society. Amyotrophic Lateral Sclerosis. [Internet]. [Consultado 26 Abril 2020]. NEJM Resident 360.org. 2017. Disponible en: https://resident360.nejm.org/clinical-pearls/amyotrophic-lateral-sclerosis- 2

  7. Zapata-Zapata C, Franco-Dáger E, Solano-Atehortúa J, Ahunca-Velásquez L. Esclerosis lateral amiotrófica: actualización. SCIELO. 2016;vol.29 no.2. https://doi.org/10.17533/udea.iatreia.v29n2a08

  8. Grad L, Rouleau G, Ravits J, Cashman N. Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS). Cold Spring Harbor Perspectives in Medicine. 2016;7(8):a024117. https://doi.org/10.1101/cshperspect.a024117

  9. National Institute of Neurological Disorders and Stroke. Esclerosis lateral amiotrófica. [Internet]. [Consultado 26 abril 2020]. National Institute of Neurological Disorders and Stroke (NINDS). 2018. Disponible en: https://espanol.ninds.nih.gov/trastornos/esclerosis_lateral_amiotrofica.htm

  10. Huynh W, Dharmadasa T, Vucic S, Kiernan M. Functional Biomarkers for Amyotrophic Lateral Sclerosis. Frontiers in neurology. 2019. https://doi.org/10.3389/fneur.2018.01141

  11. Gálvez N, Goya N, Cudkowicz, M. Disease-modifying treatment of amyotrophic lateral sclerosis. [Internet]. [Consultado 26 abril 2020]. UpToDate [Internet]. 2020. Disponible en: https://www.uptodate.com/contents/disease-modifying-treatment-of-amyotrophic-lateral-sclerosis/print

  12. Statland J, Moore D, Wang Y, Walsh M, Mozaffar T, Elman L et al. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Pudmed Muscle & Nerve. 2018;59(2):201-207. https://doi.org/10.1002/mus.26335

  13. Ferreira R. Esclerosis lateral amiotrófica [Internet]. [Consultado 27 abril 2020]. Intramed. 2019;1. Disponible en: https://www.intramed.net/contenidover.asp?contenidoid=92892

  14. Martins I. Phase 3 Trial of Masitinib as Add-on ALS Treatment Cleared by FDA [Internet]. [consultado 30 Abril 2020]. Disponible ALS News Today. 2020 en: https://alsnewstoday.com/2020/04/03/fda-clears-ab-science-toopen- phase-3-trial-of-masitinib-add-on-als-treatment/

  15. Abdul Wahid S, Law Z, Ismail N, Lai N. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2019, Issue 12. Art. No.: CD011742. https://doi.org/10.1002/14651858.CD011742.pub3

  16. Filipi, T, Hermanova Z, Tureckova J, Vanatko, , Anderova, M. Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. Journal of Clinical Medicine, 2020; 9(1), p.261. https://doi.org/10.3390/jcm9010261

  17. Glasmacher, S., Wong, C., Pearson, I. and Pal, S. Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers. JAMA Neurology, 2020; 77(3), p.367. https://doi.org/10.1001/jamaneurol.2019.3924

  18. Rosenbohm, A., Nagel, G., Peter, R., Brehme, T., Koenig, W., Dupuis, L., Rothenbacher, D. and Ludolph. Association of Serum Retinol-Binding Protein 4 Concentration With Risk for and Prognosis of Amyotrophic Lateral Sclerosis. JAMA Neurology, 75(5), p.600. https://doi.org/10.1001/jamaneurol.2017.5129




2020     |     www.medigraphic.com